Study of Dengue in Patients With Autoimmune Diseases During the Epidemics of 2020 and 2021 in Reunion Island

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-30

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is not known whether there is a different clinical profile of dengue in patients with immune system dysfunction. Preliminary data and previous literature suggest that autoimmune diseases, and in particular their treatment, may favour the evolution to severe forms of dengue.

Our research hypothesis is that the clinico-biological presentation of dengue might be different in case of autoimmune disease, either on the side of overactivation (autoimmune and auto inflammatory diseases without treatment) or immunodepression (autoimmune and auto inflammatory diseases under immunosuppressive treatment).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis?

NCT06761209

Auto-immune Hepatitis

RECRUITING

Study of Clinical Features of Patients With Autoimmune Liver Disease Complicated With Covid-19 and the Immune Mechanism Affecting Prognosis

NCT06099626

Autoimmune Liver Disease, COVID-19

UNKNOWN

Study of Acute Autoimmune Encephalitis With Positive Antibodies in Eastern France

NCT05605223

Acute Autoimmune Encephalitis

COMPLETED

Antibodies Responses to COVID-19 Infection in Hospitalized Patients

NCT04520880

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection) Hospitalized Patients Laboratory-confirmed SARS-CoV 2 Infection

UNKNOWN

Q Fever and Auto-immunity

NCT02822807

Q Fever Auto-Immunity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dengue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* Patient with autoimmune or autoinflammatory disease
* Confirmed diagnosis of dengue (in 2020 or 2021): serological test, antigenic test or PCR test to confirm the diagnosis according to current criteria

Exclusion Criteria

* minor
* opposition to the re-use of data
* patient not followed in Reunion
* protected adult (guardianship or curatorship) or under legal protection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No